ArticleJournal of clinical medicine2019
Metabolic Syndrome Resolved within Two Years is Still a Risk Factor for Kidney Cancer.
Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- Metabolic syndrome and increased susceptibility to renal cell carcinoma - a meta-analysis.BMC nephrology · 2025Pooled it
- Association Between Metabolic Syndrome and Risk of Renal Cell Cancer: A Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Exploring the association between metabolic syndrome, its components and subsequent cancer incidence: A cohort study in Catalonia.Cancer medicine · 2024Article
- Association between metabolic syndrome and kidney cancer risk: a prospective cohort study.Lipids in health and disease · 2024Article
- Association of Metabolic Syndrome Components and Nutritional Status with Kidney Cancer in Young Adult Population: A Nationwide Population-Based Cohort Study in Korea.Biomedicines · 2023Article
- Implications of metabolic health status and obesity on the risk of kidney cancer: A nationwide population-based cohort study.Frontiers in endocrinology · 2022Article
- Association between metabolic syndrome and 13 types of cancer in Catalonia: A matched case-control study.PloS one · 2022Article
- Association of metabolic syndrome and the risk of bladder cancer: A prospective cohort study.Frontiers in oncology · 2022Article
- Changes in metabolic syndrome status and risk of laryngeal cancer: A nationwide cohort study.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The prevalence of metabolic syndrome (MetS) and kidney cancer is increasing, but studies on the effects of MetS and its components on kidney cancer development have had ambiguous results. Overall, 7,613,865 patients from the Korean National Health Insurance System were analyzed and followed up until 2017. Patients with 3 of the necessary five components of MetS were diagnosed with MetS. Patients were divided into subgroups according to two consecutive physical examinations conducted every two years. The Cox proportional hazard regression model was used to survey the independent association between MetS and the risk of kidney cancer development. Kidney cancer risk was significantly higher in patients with MetS, and there was no difference according to sex. The hazards ratio of kidney cancer increased with increasing number of MetS components. For patients not diagnosed with MetS but with abdominal obesity and hypertension, the likelihood of developing kidney cancer was similar to that of patients diagnosed with MetS. Patients with improved MetS within two years had increased risk of kidney cancer compared with those without MetS. MetS is an independent risk factor for kidney cancer, and the obesity and hypertension components of MetS are also powerful risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.